Grants and contracts awarded to Yale School of Medicine

September/October 2005


  • Nadia Abdala, NIH, Identifying HIV-Bridge-Population in STI Clinics in Russia, 2 years, $148,797
  • Ronald Braithwaite, NIH, Defining the Threshold for Alcohol-Induced Nonadherence in HIV+ Patients, 2 years, $340,221
  • Catalin Buhimschi, NIH, Mechanisms of Myometrial Healing and Regeneration, 2 years, $163,500
  • Kathleen Carroll, NIH, Clinical Trials Network: New England Node, 5 years, $6,200,278
  • Gary Cline, NIH, Metabolic and Mitochondrial Defects of Islet Beta-Cell of MODY-3, 4 years, $1,070,622
  • James Comer, Dept. of Education, Integrating Instructional Strategies with Systemic Reform, 3 years, $1,327,331
  • Joseph Craft, NIH, CNS Lupus: Mechanistic Dissection, 2 years, $414,984
  • Francesco D’Errico, NIH, Chemotherapy with Injectable Microdroplets, 1 year, $169,985
  • Sabrina Diano, NIH, Learning and Memory in the Melanocortin System, 4 years, $1,308,000
  • Ronald Duman, NIH, Profiling Gene Expression in Major Depression, 4 years, $1,182,871
  • James Duncan, NIH, Image Analysis for Adaptive Prostate Radiotherapy, 4 years, $1,824,710
  • Jack Elias, NIH, AMCase and BRP-39 in Th2 Inflammation and Asthma, 4 years, $1,635,000
  • Donald Engelman, NIH, A High-Capacity Screen for Membrane-Active Compounds, 1 year, $204,375
  • Paul Falzer, NIH, Image Theory in Disseminating Evidence-Based Practices, 3 years, $381,420
  • David Fiellin, NIH, Counseling for Primary Care Office-Based Buprenorphine, 5 years, $2,975,029
  • Erol Fikrig, NIH, Immune Function and Biodefense in Children, Elderly and Immunocompromised Populations, 5 years, $11,518,083
  • Brian Forsyth, NIH, Promoting Resilience in Young Children of HIV-Infected Mothers in South Africa, 5 years, $2,804,291
  • Shawn Fultz, NIH, Markers of Alcohol Toxicity in HIV-Infected Veterans, 2 years, $341,479
  • Ya Ha, NIH, The Structural Basis for APP Cleavability, 5 years, $1,430,625
  • Theodore Holford, NIH, Modeling Interventions for Lung Cancer Mortality, 5 years, $1,251,389
  • Tamas Horvath, NIH, Central Peptidergic Circuits in Metabolism Regulation, 3 years, $858,375
  • Hetal Kocinsky, NIH, The Role of Phosphorylation in the Regulation of NHE3, 5 years, $718,875
  • Michael Kozal, NIH, Hepatitis C Microarrays to Detect Drug Resistance, 2 years, $358,600
  • Diane Krause, NIH, Yale Center of Excellence in Molecular Hematology, 5 years, $4,985,073
  • Paul Lizardi, NIH, Global DNA Methylation Profiles of Head and Neck Cancers, 1 year, $138,975
  • Steven Marans,Center for Mental Health Services, SAMHSA Childhood Violent Trauma Center, 4 years, $600,000
  • Sherry McKee, NIH, Investigating Tobacco and Alcohol Use Behaviors Across the Continuum of Use, 2 years, $145,500
  • Thomas McMahon, NIH, Parent Intervention for Drug-Abusing Fathers, 4 years, $1,371,621
  • David Morris, NIH, High Throughput Molecular Screening for Compounds that Alter TGFb1 Signaling, 1 year, $204,375
  • David Musto, NIH, Previous American Drug Experience and Future Perspectives, 5 years, $715,334
  • Nazih Nakhoul, Tulane University, Membrane Transport of NH3 and NH4+, 5 months, $15,280
  • Marina Picciotto, NIH, Nicotine Addiction in Mice Lacking the Neuronal nAChR, 5 years, $1,635,000
  • Marc Potenza, NIH, fMRI of CBT and CM for Cocaine Dependence, 5 years, $1,822,059
  • Carrie Redlich, NIH, Program for Patient-Oriented Environment Health Research and Training, 5 years, $896,295
  • Richard Schottenfeld, NIH, Improving Efficacy of Drug Abuse Treatment, 4.5 years, $777,091
  • Peter Schwartz, Health Resources and Services Administration, Yale Ovarian Cancer and Early Detection Program, 1 year, $392,826
  • Robert Sherwin, NIH, Islet Transplantation and CNS Metabolism in Hypoglycemia, 3 years, $1,376,105
  • Stefan Somlo, NIH, Yale Center for the Study of Polycystic Kidney Disease, 5 years, $5,619,720
  • Sandra Springer, NIH, Opiate Dependence, HIV and Adherence Interventions, 1 year, $835,292
  • Tami Sullivan, NIH, The Temporal Relationship of Partner Violence and Drug Use, 5 years, $828,329
  • Ning Tian, NIH, NMDA Receptor and Synaptic Plasticity in Retina, 3 years, $490,500
  • Mary Tinetti, NIH, Need for Tailored Clinical Trials: Hypertension and Fall Risk, 2 years, $367,131
  • Vinzenz Unger, NIH, Structure and Function of Copper Transporters, 4 years, $1,216,957
  • John Wysolmerski, NIH, Recovery of Bone Mass After Lactation, 2 years, $327,000
  • Heping Zhang, NIH, Data Management, Statistics and Informatics Core, 5 years, $10,021,496
  • Tongzhang Zheng, NIH, Occupational Exposure and NHL Risk, 1 year, $9,600

  • Serap Aksoy, World Health Organization, Glossina Developmental-Stage-Specific EST Project, 1 year, $5,000
  • Luis Anez, State of CT Dept. of Mental Health and Addiction Services, Connecticut Co-Occurring State Incentive Grant, 1 year, $260,000
  • Abdallah Badou, Boehringer Ingelheim Pharmaceuticals, Inc., Th1 Cells, 1 year, $180,000
  • Samuel Ball, National Alliance for Research on Schizophrenia and Depression, Psychotic Spectrum Personality Disorders in Homeless Persons, 2 years, $99,888
  • Kevin Behar, Children’s Hospital of Pittsburgh Foundation, Murine Succinate Semialdehyde Dehydrogenase Deficiency, and Epileptic Disorder with Elevated CNS GABA, 1 year, $12,435
  • Zubin Bhagwagar, National Alliance for Research on Schizophrenia and Depression, Serotonin and Vulnerability to Bipolar Disorder, 1 year, $27,885
  • Walter Boron, Regents of the University of California, Bicarbonate Transport in Neurons and Astrocytes in Hypoxia, 1 year, $243,540
  • Yung-Chi Cheng, National Foundation for Cancer Research, National Foundation for Cancer Research Fellowship, 5 years, $375,000
  • R. Todd Constable, Pfizer, Inc., Validation of Next Generation and Analysis Tools for Brain Perfusion, 1 year, $517,559; Pfizer, Inc., Test-Retest Variability of fMRI Measures of Working Memory in Healthy Volunteers, 4 months, $275,249
  • Larry Davidson, State of CT Dept. of Mental Health and Addiction Services, Connecticut Mental Health Transformation State Incentive Grant, 1 year, $863,079 Michael DiGiovanna, The Breast Cancer Research Foundation, Activated HER2 as a Predictor of Therapeutic Response and as a Target in Novel Combination Therapies, 1 year, $249,343
  • Ralph DiLeone, National Alliance for Research on Schizophrenia and Depression, The Role of Nucleus Accumbens MCH Signaling in Modulating Mood and Depression, 1 year, 30,000
  • Naomi Driesen, Pfizer, Inc., The Effect of Ketamine and Glycine on Working Memory in Healthy Subjects, 8 months, 257,582
  • Barbara Ehrlich, Robert Leet and Clara Guthrie Patterson Trust, A New Role for the Anti-Cancer Drug Taxol on Calcium Signaling and Peripheral Neuropathy, 1 year, $60,000
  • Jack Elias, Amrad Corporation Ltd., Role of IL-11 in Asthma, 2.5 years, $247,612
  • David Fiellin, Robert Wood Johnson Foundation, Evaluating Medicaid and Public Funding for Buprenorphine Treatment of Opioid Dependence, 3 years, $292,396
  • Tony George, National Alliance for Research on Schizophrenia and Depression, Effects of Galanthamine on Neurocognitive Deficits in Smokers and Non-Smokers with Schizophrenia, 2 years, $99,391
  • Frank Giordano, Boehringer Ingelheim Pharmaceuticals, Inc., Pharmacological Manipulation of HIF, 2 years, $360,000
  • Nora Groce, UNICEF New York, UNICEF Violence Against Children Consultation, 6 months, $9,500
  • Steven Hebert, Boehringer Ingelheim Pharmaceuticals, Inc., Mouse Kidney Physiology, 2 years, $180,000
  • Richard Hochberg, Wake Forest University School of Medicine, Androgen Receptor-Mediated Detection of Cancer Using PET, 1 year, $49,697
  • Beth Jones, University of Miami, Psychosocial Factors, Race, and Cancer Survival, 6 months, $14,728
  • Susan Kaech, Cancer Research Institute, Determining the Role of IL-7 Signaling in Memory CD8 T-cell Development During Acute and Chronic Viral Infection, 4 years, $200,000
  • Daniel Kaplan, The Lupus Research Institute, Involvement of Plasmacytoid DCs in the Development of LE (Lupus Erythematosis), 3 years, $300,000
  • Michael Kashgarian, University of California-San Diego, Hypoxia in Development: Injury in Adaptation Mechanisms, 5 years, $70,093
  • Steven Kendell, National Alliance for Research on Schizophrenia and Depression, Measurement of Riluzole Impact Upon Cortical Amino Acid Neurotransmitter Levels in Treatment-Resistant Major Depressive Disorder, 2 years, $60,000
  • James Mazer, Whitehall Foundation, Inc., The Neural Basis of Natural Vision, 3 years, $224,000
  • Godfrey Pearlson, Meharry Medical College, Meharry Alcohol Research Collaborative, 1 year, $7,711
  • Jordan Pober, Boehringer Ingelheim Pharmaceuticals, Inc., Endothelial Cells and Cardiac Myocytes, 1 year, $90,000
  • Alan Sartorelli, National Foundation for Cancer Research, Role of Transcription Factor Scl in Sensitivity of Leukemia Cells to All-trans Retinoic Acid/LiCl Induced Differentiation, 1 year, $50,000
  • Gerald Shadel, Ohio State University, Induction of Inflammation by Mitochondrial Proteins, 1 year, $8,019
  • Gordon Shepherd, Weill Medical College of Cornell University, Neuroinformatic-based Neuroscience Information Framework, 1 year, $125,000
  • Warren Shlomchik, Medarex, Inc., Novel Immunotoxins for Depletion of Dendritic Cells, 1 year, $60,000
  • Norman Siegel, University of California-San Diego, Renal Tolerance to Anoxia/Ischemia, 5 years, $240,531
  • Albert Sinusas, Juvenile Diabetes Research Foundation International, Targeted Imaging of Angiogenesis and Angiogenic Therapy in Type 1 Diabetes, 1 year, $110,000
  • Stephen Strittmatter, The Amyotrophic Lateral Sclerosis Association, Nogo and Nogo Receptor in Transgenic ALS, 1 year, $97,633
  • Michael Tal, Pfizer, Inc., Pancreatic Beta Cell Mass and Function Quantification by Means of Perfusion Imaging, 2 years, $938,000
  • Nadia Ward, State of CT Dept. of Higher Education, Maximizing Adolescent Academic Excellence, 1 year, $149,500; University of Connecticut, Maximizing Adolescent Academic Excellence, 1 year, $70,000
  • Robert Weiss, Interstital Cystitis Association, Signaling Pathways in the Urothelium of IC Patients Causing Decreased Urinary Cyclic GMP, 1 year, $10,450
  • Kimberly Yonkers, National Alliance for Research on Schizophrenia and Depression, A Controlled Study of SSRI Exposure in Neonates, 2 years, $102,756